Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 12,000 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Sarchi also recently made the following trade(s):

• On Thursday, April 2nd, Christopher Sarchi sold 6,500 shares of Replimune Group stock. The stock was sold at an average price of $8.01, for a total value of $52,065.00.

Replimune Group Stock Up 12.5%

Shares of NASDAQ REPL opened at $9.98 on Thursday. The company has a market capitalization of $824.05 million, a price-to-earnings ratio of -2.90 and a beta of 0.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The business has a 50-day moving average of $5.02 and a two-hundred day moving average of $7.26. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $13.24.

Analyst Ratings Changes

A number of brokerages have issued reports on REPL. BMO Capital Markets downgraded Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a research report on Friday, May 29th. HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Finally, Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Seven analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $4.88.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group in the 4th quarter valued at about $29,000. CWM LLC increased its position in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the period. Essential Partners LLC increased its position in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares during the period. BNP Paribas Financial Markets increased its position in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Replimune Group in the 2nd quarter valued at about $69,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.